PMC:7212965 / 1506-1786 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":190,"end":195},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":".2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) an"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T5","span":{"begin":190,"end":195},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":".2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) an"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T15","span":{"begin":190,"end":195},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T16","span":{"begin":190,"end":195},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":".2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) an"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":227,"end":236},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_132943"},{"id":"A5","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_29995"},{"id":"A6","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_72314"}],"text":".2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) an"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T8","span":{"begin":11,"end":26},"obj":"Phenotype"},{"id":"T9","span":{"begin":57,"end":71},"obj":"Phenotype"},{"id":"T10","span":{"begin":190,"end":209},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0001392"}],"text":".2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) an"}

{"project":"LitCovid-sentences","denotations":[{"id":"T13","span":{"begin":98,"end":145},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":".2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) an"}

{"project":"LitCovid-PubTator","denotations":[{"id":"56","span":{"begin":136,"end":144},"obj":"Species"},{"id":"58","span":{"begin":11,"end":17},"obj":"Disease"},{"id":"59","span":{"begin":18,"end":26},"obj":"Disease"},{"id":"60","span":{"begin":57,"end":71},"obj":"Disease"},{"id":"61","span":{"begin":181,"end":209},"obj":"Disease"}],"attributes":[{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"Tax:9606"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:D009325"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"MESH:D014839"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"MESH:D015746"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:D006973"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":".2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) an"}